Wnt5a is elevated in heart failure and affects cardiac fibroblast function
Wnt signaling is dysregulated in heart failure (HF) and may promote cardiac hypertrophy, fibrosis, and inflammation. Blocking the Wnt ligand Wnt5a prevents HF in animal models. However, the role of Wnt5a in human HF and its functions in cardiac cells remain unclear. Here, we investigated Wnt5a regulation in HF patients and its effects on primary mouse and human cardiac fibroblasts. Serum Wnt5a was elevated in HF patients and associated with hemodynamic, neurohormonal, and clinical measures of disease severity. In failing human hearts, Wnt5a protein correlated with interleukin (IL)-6 and tissue inhibitor of metalloproteinase (TIMP)-1. Wnt5a messenger RNA (mRNA) levels were markedly upregulated in failing myocardium and both mRNA and protein levels declined following left ventricular assist device therapy. In primary mouse and human cardiac fibroblasts, recombinant Wnt5a dose-dependently upregulated mRNA and protein release of IL-6 and TIMP-1. Wnt5a did not affect β-catenin levels, but activated extracellular signal-regulated kinase 1/2 (ERK1/2) signaling. Importantly, inhibition of ERK1/2 activation attenuated Wnt5a-induced release of IL-6 and TIMP-1. In conclusion, our results show that Wnt5a is elevated in the serum and myocardium of HF patients and is associated with measures of progressive HF. Wnt5a induces IL-6 and TIMP-1 in cardiac fibroblasts, which might promote myocardial inflammation and fibrosis, and thereby contribute to HF progression.
• Wnt5a is elevated in serum and myocardium of HF patients and is associated with measures of progressive HF.
• In cardiac fibroblasts, Wnt5a upregulates interleukin (IL)-6 and tissue inhibitor of metalloproteinase (TIMP)-1 through the ERK pathway.
• Wnt5a-mediated effects might promote myocardial inflammation and fibrosis, and thereby contribute to HF progression.
KeywordsWnt5a Wnt signaling Heart failure Il-6 TIMP-1 ERK
We are grateful to the patients and the animal facility staff at Oslo University Hospital, Oslo, Norway, for contributing to our research.
This work was supported by the South-Eastern Norway Regional Health Authority [grant number 2013041], the Research Council of Norway, Anders Jahre’s Fund for the Promotion of Science, Norway, and the Simon Fougner Hartmanns Family Fund, Denmark.
Compliance with ethical standards
Human studies conformed to the Declaration of Helsinki and were approved by the South Eastern Regional Committee for Medical and Health Research Ethics. Written informed consent was obtained from all individuals. Animal experiments were approved by the animal research committee and were carried out in accordance with institutional guidelines and conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 2011).
Conflict of interest
The authors declare that they have no competing interests.
- 12.Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC, Smits JF, Blankesteijn WM (2011) Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation 124:1626–1635CrossRefPubMedGoogle Scholar
- 13.Hermans K, Uitterdijk A, de Wijs-Meijler D, Daskalopoulos E, Verzijl A, Sneep S, Blonden L, Reiss I, Duncker D, Blankesteijn WM et al (2015) UM206, a Peptide Fragment of Wnt5a, Attenuates Adverse Remodeling after Myocardial Infarction in Swine. The FASEB Journal 29Google Scholar
- 20.Askevold ET, Aukrust P, Nymo SH, Lunde IG, Kaasboll OJ, Aakhus S, Florholmen G, Ohm IK, Strand ME, Attramadal H et al (2014) The cardiokine secreted frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure. J Intern Med 275:621–630CrossRefPubMedGoogle Scholar
- 27.Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW et al (2006) Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114:1883–1891CrossRefPubMedGoogle Scholar
- 31.Hartford M, Wiklund O, Mattsson Hulten L, Persson A, Karlsson T, Herlitz J, Caidahl K (2007) C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med 262:526–536CrossRefPubMedGoogle Scholar
- 34.Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P et al (2005) Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112:1136–1144CrossRefPubMedGoogle Scholar
- 46.Tsutsui H, Kinugawa S, Matsushima S (2008) Oxidative stress and mitochondrial DNA damage in heart failure. Circ J 72 Suppl A: A31-37Google Scholar
- 48.Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED (2013) A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl) 91:1315–1327CrossRefGoogle Scholar
- 49.Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, Cleland JG, McMurray JJ, Aukrust P, Ueland T (2015) Secreted frizzled related protein 3 in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS One 10:e0133970CrossRefPubMedPubMedCentralGoogle Scholar